## ALLEGATO 2 - SCHEDA INFORMATIVA “BIOMEDICINA TRASLAZIONALE” - ANNEX 2 INFORMATION SHEET “TRASLATIONAL BIOMEDICINE”

**DOTTORATO DI RICERCA - PH.D. COURSE**

**BIOMEDICINA TRASLAZIONALE / TRASLATIONAL BIOMEDICINE**

**CICLO - CYCLE**

39°

**COORDINATORE - COORDINATOR**

PROF. CARLO VANCHERI

**DURATA - DURATION**

TRE (3) ANNI - THREE (3) YEARS

**DIPARTIMENTO DI AFFERENZA - DEPARTMENT**

DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE - DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE

**SITO WEB DEL DOTTORATO - PH.D. WEBSITE**

https://www.medclin.unict.it/it/content/dottorato-di-ricerca

**MODALITÀ DI SELEZIONE DEI CANDIDATI - VALUTAZIONE DEI TITOLI E PROVA ORALE - CANDIDATES SELECTION PROCEDURES - EVALUATION OF QUALIFICATIONS AND ORAL EXAMINATION**

**DATA DELLA PROVA ORALE / ORAL EXAMINATION DATE**

06/07/2023 - July 6th 2023

**ORARIO DELLA PROVA ORALE / ORAL EXAMINATION TIME**

ore 9,00 - h. 9 am (Italian time)

**LUOGO DELLA PROVA ORALE - PLACE OF THE ORAL EXAMINATION**

Torre Biologica "F. Latteri", via S. Sofia 97 - 95123 CATANIA

**LINGUA DELLA PROVA ORALE - LANGUAGE OF THE ORAL EXAMINATION**

Italiano o inglese

**POSTI DISPONIBILI - AVAILABLE PLACES**

TOTALE POSTI CON BORSA DI STUDIO: 7

6 mesi estero

TOTALE POSTI SENZA BORSA DI STUDIO: 1

**ENTE/PROGRAMMA FINANZIATORE - FUNDING INSTITUTION OR PROGRAM**

**TEMA DI RICERCA E COMPETENZE COLLEGATI ALLA BORSA - RESEARCH TOPIC AND SKILLS RELATED TO THE SCHOLARSHIP**

1. **PNRR - SAMOTHRACE - SPOKE 1**
   - Evaluation of minimal residual disease in multiple myeloma patients after daratumumab-based induction therapy

2. **PNRR - INF-ACT One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases - SPOKE: 4**
   - Istituto Superiore Sanità

3. **PNRR - D.M. 118/2023, Inv. 4.1**
   - Fisiopatologia delle malattie complesse: dall'osservazione clinica ai meccanismi molecolari

4. **PNRR - D.M. 117/2023, Inv. 3.3 in collaborazione con HUMANITAS 1**
   - Fisiopatologia delle malattie complesse: dall'osservazione clinica ai meccanismi molecolari

5. **PNRR - D.M. 117/2023, Inv. 3.3 in collaborazione con HUMANITAS 2**
   - Fisiopatologia delle malattie complesse: dall'osservazione clinica ai meccanismi molecolari

6. **POSTO SENZA BORSA DI STUDIO - PLACE WITHOUT SCHOLARSHIP**

TOTALE POSTI CON BORSA DI STUDIO, TOTAL: 7

18 mesi presso HUMANITAS e 6 mesi estero

**INFORMAZIONI AGGIUNTIVE - ADDITIONAL INFORMATION**

- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy
- Evaluation of residual minimal disease in multiple myeloma patients after daratumumab-based induction therapy